AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00889889 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell-Derived Trivalent Subunit Influenza Vaccine
Description: surface antigen, inactivated, prepared in cell cultures
Study NCT00889889 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02581462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLOT alone
Description: Pre-operative therapy:~* Docetaxel 50 mg/m², d1, d15, d29, d43~* Oxaliplatin 85 mg/m², d1, d15, d29, d43~* Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)~* 5-FU 2600 mg/m², d1, d15, d29, d43~Surgery is recommended to be scheduled 4 weeks after d43.~Post-operative therapy (start 6 to 8 weeks after surgery):~* Docetaxel 50 mg/m², d1, d15, d29, d43~* Oxaliplatin 85 mg/m², d1, d15, d29, d43~* Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)~* 5-FU 2600 mg/m², d1, d15, d29, d43
Study NCT02581462 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FLOT + Herceptin/Pertuzumab
Description: Pre-operative therapy:~* Herceptin 8/6 mg/kg, d1, d22, d43~* Pertuzumab 840 mg, d1, d22, d43~* Docetaxel 50 mg/m², d1, d15, d29, d43~* Oxaliplatin 85 mg/m², d1, d15, d29, d43~* Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)~* 5-FU 2600 mg/m², d1, d15, d29, d43~Surgery is recommended to be scheduled 4 weeks after d43.~Post-operative therapy (start 6 to 8 weeks after surgery):~* Herceptin 8/6 mg/kg, d1, d22, d43~* Pertuzumab 840 mg, d1, d22, d43~* Docetaxel 50 mg/m², d1, d15, d29, d43~* Oxaliplatin 85 mg/m², d1, d15, d29, d43~* Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)~* 5-FU 2600 mg/m², d1, d15, d29, d43.
Study NCT02246192 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sinus pilonidal excision+ PRGF
Description: open sinus pilonidal excision and plasma rich grow factor infiltration intra and postoperatively
Study NCT02246192 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sinus pilonidal excision and standard cares
Description: sinus pilonidal excision and postoperative standard care with povidone daily
Study NCT00828399 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glutamine
Description: Oral glutamine 30g/day
Study NCT00828399 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Whole protein
Description: Oral whole protein 30 g/day
Study NCT02128243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 de-escalation
Description: S-1 30 mg/m² bid d1-14 q21d
Study NCT02128243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy by Investigator's choice
Description: Polychemotherapy administration as in induction therapy consists of a platinum and fluoropyrimidine compound as well as optional a taxane / an anthracycline compound.~Two-Drug combinations:~FLO / mod. FOLFOX-6; Cisplatin, S-1; Cisplatin, 5-FU; Cisplatin, Capecitabine (XP)~Three-drug combinations:~EOX/EOF FLOT
Study NCT02267304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mL of sodium chloride (0,9%)
Study NCT04169945 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasonic instrumentation
Description: Full mouth root surface debridement
Study NCT04169945 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Air polishing with erythritol powder
Description: Air flow PLUS
Study NCT02267304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine 0,05mg/kg
Study NCT02267304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone 10mg
Study NCT00892203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGG492
Study NCT00892203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sumatriptan
Study NCT00892203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01838785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DTBZ AV-133
Study NCT02120963 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Person-centered physical therapy intervention program
Description: Comparison of person-centered physical therapy and control group
Study NCT04757948 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture of acupoints P-6 and St-36
Study NCT04757948 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: TENS of acupoints P-6 and St-36
Study NCT04757948 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham-TENS
Description: Sham-TENS of acupoints P-6 and St-36
Study NCT00289198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF
Description: fluticasone furoate 110 μg nasal spray
Study NCT00289198 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo nasal spray
Study NCT02270723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% Human Albumin  Behring
Description: Intravenous infusion of 5% Human Albumin during major surgery
Study NCT02270723 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactated Ringer
Description: Intravenous infusion of Lactated Ringer during major surgery
Study NCT02804750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT125134
Study NCT03156738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive a single IV dose of placebo
Study NCT03194191 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture needles
Description: The patient will be in a semi recumbent position during needle penetration. Duration of needle insertion: 30 minutes
Study NCT03194191 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Acupuncture needles
Description: The patient will be in a semi recumbent position during needle penetration. Duration of needle insertion: 30 minutes
Study NCT01478841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: polyphenol
Description: 2 capsules of 0.5 gram to be taken at the beginning of breakfast and dinner (2g/day) fructose : dose of 3 g/kg/day from D57 to D62 in the form of a 20% solution taken during the three main meals
Study NCT01478841 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 capsules of 0.5 gram to be taken at the beginning of breakfast and dinner (2g/day) fructose : dose of 3 g/kg/day from D57 to D62 in the form of a 20% solution taken during the three main meals
Study NCT00504790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK923295
Description: anti-mitotic compound
Study NCT03730077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FMISO
Description: 18F-FMISO PET/CT
Study NCT03936699 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Nerve Stimulator (TENS)
Description: The Elira wearable patch system is a Radio Frequency (RF) coupled, wearable transcutaneous electrical nerve stimulator (TENS) device controlled via Bluetooth by a smart phone unit running a custom application which directs therapy from the patch within safe limits set by a clinician and also includes a weight loss diary.~Behavioral: Diet \& Exercise Subjects to be instructed on a healthy 1200 calorie diet.
Study NCT03936699 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet & Exercise
Description: Subjects to be instructed on a healthy 1200 calorie diet.
Study NCT03936699 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet & Exercise
Description: Subjects to be instructed on a healthy 1200 calorie diet.
Study NCT05118100 — intervention group
Intervention type: DRUG
Intervention: Clearfil Protect Bond
Description: An adhesive is used routinely when placing resin composite restorations. This group receives a commercially available adhesive containing an antibacterial monomer (MDPB)
Study NCT05118100 — intervention group
Intervention type: DRUG
Intervention: Clearfil SE Bond
Description: An adhesive is used routinely when placing resin composite restorations. This group receives a commercially available adhesive.
Study NCT00068107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Replagal
Description: enzyme replacement therapy
Study NCT01419184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Study NCT01419184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Study NCT02662816 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proton magnetic resonance spectroscopy (1H MRS)
Study NCT02662816 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: a protein rich breakfast at home
Study NCT02662816 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: a protein rich lunch at the Clinical Investigation Center
Study NCT04417075 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Impacto (Mobile App)
Description: This is the mobile app to be developed and evaluated in this project. It is designed for Spanish-speaking, Latinx smokers with high anxiety sensitivity and will be built for the Android platform. The app will include components to address and remediate anxiety sensitivity, as well as having smoking cessation components.
Study NCT04417075 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dejar de Fumar Asistente (Mobile App)
Description: Dejar de Fumar Asistente (English version called: Quit Tracker: Stop Smoking) is a popular, free third party mobile application aimed at helping smokers quit smoking. This is the mobile app that will serve as the control condition in evaluating the efficacy of Impacto. This mobile app is well established as a smoking cessation app for Spanish-speaking, Latinx smokers. The app includes smoking cessation components but does not have a specific emphasis on anxiety sensitivity.
Study NCT01098877 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PF-04634817 Placebo
Description: Oral solution, placebo, single dose
Study NCT01098877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04634817
Description: Oral solution, 1mg, single dose
Study NCT01098877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04634817
Description: Oral solution, 3mg, single dose
Study NCT01098877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04634817
Description: Oral solution, 10mg, single dose
Study NCT01098877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04634817
Description: Oral solution, 30mg, single dose
Study NCT01098877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04634817
Description: Oral solution, 100mg, single dose
Study NCT02661958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S6G5T-3
Description: once a day topical cream
Study NCT02661958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S6G5T-1
Description: once a day topical cream
Study NCT02661958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S6G5T-5
Description: once a day topical cream
Study NCT02661958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S6G5T-6
Description: once a day topical cream
Study NCT02661958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S6G5T-7
Description: once a day topical cream
Study NCT01098877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04634817
Description: Oral solution, 300mg, single dose
Study NCT01098877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04634817
Description: Oral solution, 600mg, single dose
Study NCT02661958 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: S6G5T-8
Description: once a day topical cream
Study NCT01187888 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rasagiline
Description: tablet once daily 1 mg 1 year
Study NCT01187888 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: tablet once daily one year
Study NCT01327014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XueZhiKang (XZK), a botanic product with multiple components
Description: 4 capsules of study drug twice a day for 12 weeks.
Study NCT01327014 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 capsules twice a day for 12 weeks.
Study NCT02099409 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLORENCED2
Description: FLORENCED2 device ensures the closed loop between Freestyle Navigator II and the DANA DIABECARE R
Study NCT02434991 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Barostat
Description: * During this study, the investigators will ask you to fill out questionnaires about your swallowing, chest pain, and heartburn. The investigators hope the patient will answer all of the questions, but patients can skip any questions they do not want to answer. The questionnaires will take about 15 minutes to complete.~* A urine pregnancy test for females of childbearing years.~* Patients will be asked to fast overnight (nothing to eat or drink for 8 hours) prior to the barostat test.~* At this point healthy controls have completed the study.~* Patients with achalasia will then undergo treatment for achalasia at the discretion of the primary clinician managing their case.~* Patients will be contacted to complete a phone survey 3 \& 6 months and 2 \& 4 years after treatment.
Study NCT00539084 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MicronJet
Description: The MicronJet is a microneedle injection device designed for intradermal delivery of drugs (i.e. delivery into the layers of the skin). In this study the MicronJet will be used to inject Lidocaine or Saline.
Study NCT00539084 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: MicronJet
Description: The MicronJet is a microneedle injection device designed for intradermal delivery of drugs (i.e. delivery into the layers of the skin). In this study the MicronJet will be used to inject Lidocaine or Saline.
Study NCT00074425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BufferGel
Description: Participants will be given single-use, prefilled applicators of gel and will be instructed to apply one dose of BufferGel intravaginally up to 60 minutes before each vaginal intercourse while in the study.
Study NCT01098877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04634817
Description: Oral solution, 900mg, single dose
Study NCT01098877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04634817
Description: Oral solution, up to 900mg, single dose after food
Study NCT01098877 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PF-04634817 Placebo
Description: Oral solution, placebo, single dose after food
Study NCT00074425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO 2000/5 Gel
Description: Participants will be given single-use, prefilled applicators of gel and will be instructed to apply one dose of PRO 2000/5 Gel intravaginally up to 60 minutes before each vaginal intercourse while in the study.
Study NCT00074425 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: Participants will be given single-use, prefilled applicators of gel and will be instructed to apply one dose of PRO 2000/5 Gel intravaginally up to 60 minutes before each vaginal intercourse while in the study.
Study NCT04393571 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile application
Description: telemedicine is used to overcome distance when patients must travel to receive specialized care. We depend on the available, widely used smartphones via a mobile application to conduct follow up data as regard to patient quality of life and comparing this to conventional follow up visits and whether it help to obtain a complete follow up data
Study NCT00249405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram + MI
Description: 14-week citalopram treatment + Motivational Interview (MI) and 9 brief sessions of a manual-guided Compliance Enhancement Therapy; post-treatment follow-up assessments will be conducted at 4, 12 and 24 weeks.
Study NCT00249405 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + MI
Description: placebo + single Motivational Interview (MI) and 9 brief sessions of a manual-guided Compliance Enhancement Therapy; post-treatment follow-up assessments will be conducted at 4, 12 and 24 weeks.
Study NCT04955054 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: diagnose
Description: Patients from UAP and AMI meet the criteria of UAP or STEMI.
Study NCT04810832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evoked related potentials
Description: Evoked related potentials are performed for each patient during each paradigm (neutral voice and expressive voices):~* with scalp electrodes in the department of neurophysiology~* with intracranial electrodes in the department of neurosurgery.
Study NCT01456156 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: postoperative radiotherapy
Description: IMRT or 3DCRT, 50-60Gy to the tumor bed
Study NCT03397134 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo administered as a single dose once daily
Study NCT03397134 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Roluperidone 32 mg
Description: Roluperidone administered as a single dose once daily
Study NCT03397134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roluperidone 32 mg
Description: Roluperidone administered as a single dose once daily
Study NCT03397134 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Roluperidone 64 mg
Description: Roluperidone administered as a single dose once daily
Study NCT03397134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roluperidone 64 mg
Description: Roluperidone administered as a single dose once daily
Study NCT02757443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phosphocreatine sodium tetrahydrate after anaesthesia induction
Description: after anaesthesia induction 2 g of Phosphocreatine (PCr) prepared in 50 mL of glucose 5% during 30 min intravenous (IV)
Study NCT02757443 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5% Glucose after anaesthesia induction
Description: after anaesthesia induction 50 mL of glucose 5% IV delivered by an identical infusion pump during 30 minutes
Study NCT02757443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phosphocreatine sodium tetrahydrate added to cardioplegia
Description: together with cardioplegia 2.5 g of PCr prepared in 50 mL of glucose 5% and added to every 1 L of cardioplegic solution (Custodiol, Dr. F. KOHLER CHEMIE, GmbH, Germany; concentration = 10 mmol/L)
Study NCT02757443 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5% Glucose
Description: together with cardioplegia 50 mL of glucose 5% is added in every 1 L of cardioplegic solution (Custodiol, Dr. F. KOHLER CHEMIE, GmbH, Germany)
Study NCT02757443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phosphocreatine sodium tetrahydrate after heart recovery
Description: immediately after heart recovery (spontaneous or paced myocardium contraction) after aorta declamping 2 g of PCr prepared in 50 mL of glucose 5% during 30 min IV
Study NCT02757443 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5% Glucose after heart recovery
Description: immediately after heart recovery (spontaneous or paced myocardium contraction) after aorta declamping 50 mL of glucose 5% IV delivered by an identical infusion pump during 30 minutes
Study NCT02757443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phosphocreatine sodium tetrahydrate after ICU admission
Description: immediately after ICU admission 4 g of PCr in 100 mL of glucose 5% during 60 min IV
Study NCT02757443 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5% Glucose after ICU admission
Description: immediately after ICU admission 100 mL of glucose 5% IV delivered by an identical infusion pump during 60 minutes
Study NCT03287674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.
Study NCT03287674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m2 is administered on day -5 to day -1.
Study NCT03287674 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIL infusion
Description: The maximum number of expanded TILs are infused over 30-45 minutes on day 0.
Study NCT03287674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Interleukin-2 is administered as a daily low-dose subcutaneous injection of 2 MIU for a total of 14 days.
Study NCT03287674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: One dose of Ipilimumab 3 mg/kg is administered 14 days prior to surgical removal of tumor tissue for TIL expansion.
Study NCT03287674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3 mg/kg is administered on day -2 before TIL infusion and every 2 weeks for a total of 4 doses.